Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the effectiveness of oral risperidone versus long-acting injectable risperidone in treating people with first-episode schizophrenia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, Los Angeles
• Collaborators: Janssen Scientific Affairs, LLC; National Institute of Mental Health (NIMH); Ortho-McNeil Janssen Scientific Affairs, LLC
• Treatments: Risperidone

Criteria

Inclusion Criteria:

• DSM-IV diagnosis of schizophrenia, schizoaffective disorder (depressed type), or schizophreniform disorder

• First major episode of psychotic symptoms occurred within 2 years prior to study entry

• Participant in the UCLA Center for Neurocognition and Emotion in Schizophrenia

Exclusion Criteria:

• Neurological disorder or injury (e.g., encephalitis, epilepsy, traumatic brain injury)

• Mental retardation (e.g., premorbid IQ less than 70)

• Significant alcohol or substance abuse within 6 months prior to study entry

• Inability to complete research measures in English

• Any condition that may make risperidone use medically inadvisable